Our re-analysis of clinical trial cohorts suggests that the Newcastle_MSI assay is more sensitive than Promega MSI V1.2 but further supports the prioritisation of IHC for LS detection in ECs due to their reduced MSI signal relative to CRC, which is particularly pronounced within inherited and sporadic MSH6-mutated tumours. Here, MSH6 is linked to neoplasm.